

## We're changing how we manage Stelara and Stelara biosimilar therapies for most commercial members, starting April 1 and May 1

Yesintek™ (ustekinumab-kfce) will be the preferred ustekinumab product for most commercial members, as follows:

- When covered under the **pharmacy benefit**, this change will be effective for dates of service on or after April 1, 2025.
- When covered under the **medical benefit**, this change will be effective for dates of service on or after May 1, 2025.

Members on a plan using the Preferred Drug List are excluded from this change. This change doesn't apply to Medicare Advantage groups or members.

In addition, for dates of service on or after May 1, 2025, the subcutaneous, or SC, formulations of ustekinumab will no longer be payable under the member's medical benefit. Members who continue to receive SC ustekinumab administered by a health care provider (billed under the medical benefit) on or after May 1 may be responsible for the full cost.

### How this will affect members under the pharmacy benefit:

Authorizations for Stelara SC, brand ustekinumab, will remain in effect until March 31, 2025. New authorizations for Yesintek SC will be approved April 1, 2025, and active through March 31, 2026, so members can continue therapy without interruption. If members decide to use Stelara SC on or after April 1, they'll be responsible for the full cost.

### Filling the prescription

We'll only pay for Yesintek SC when filled through Walgreens Specialty Pharmacy, an independent company that provides specialty pharmacy services to Blue Cross and BCN.

However, some members may be currently filling their Stelara SC prescriptions at the Michigan Medicine Specialty Pharmacy. We'll pay for Yesintek SC when filled at that pharmacy to allow those members to continue receiving this medication there.

The contact information is below.

### If members are currently filling Stelara SC through Walgreens

- Walgreens Specialty Pharmacy will obtain a new prescription for Yesintek SC from their doctor, if needed.
- Walgreens Specialty Pharmacy will fill the prescription with Yesintek SC on or after April 1.

**If members are currently filling their prescriptions through a pharmacy other than those mentioned above**

- A representative from Walgreens Specialty Pharmacy will be calling the member to set up a profile.
- Walgreens Specialty Pharmacy will obtain a new prescription for Yesintek SC from their doctor.

Prescribers can send a new prescription for Yesintek SC by one of the following methods:

Pharmacy	Methods
Walgreens Specialty Pharmacy	<ul style="list-style-type: none"> <li>• Fax: 1-866-515-1356</li> <li>• E-prescribing name: Walgreens Specialty Pharmacy – MICHIGAN</li> <li>• Contact number: 1-866-515-1355</li> </ul>
Michigan Medicine Specialty Pharmacy	<ul style="list-style-type: none"> <li>• Prescriber Fax: 734-232-3408</li> <li>• E-prescribing name: UM SPECIALTY HOME DELIVERY PHARMACY</li> <li>• Address: 7300 West Joy Road Dexter, MI 48130</li> <li>• Contact number is 1-855-276-3002</li> </ul>

**How this will affect members under the medical benefit**

The nonpreferred ustekinumab products are Imuldosa™, Otulfi™, Pyzchiva®, Selarsdi™, Stelara®, Steqeyma® and Wezlana™.

- Members who have active authorizations for the IV formulation of Yesintek won't be affected by this change.
- For members who have active authorizations for a nonpreferred ustekinumab product or SC ustekinumab product:
  - These members are authorized to continue their current therapy under the medical benefit through April 30, 2025.
  - We're proactively issuing authorizations for Yesintek SC under the pharmacy benefit from May 1, 2025, to April 30, 2026, to avoid any interruptions in care.
- Proactive authorizations for preferred therapy under the pharmacy benefit will be issued only for members who have their pharmacy benefit through Blue Cross Blue Shield of Michigan or Blue Care Network.

- Members that don't have prescription coverage through Blue Cross or BCN and are currently filling their prescription through their medical benefit, will need a new prescription with a prior authorization through their pharmacy provider.

To determine whether a group participates in the prior authorization program, see the [Specialty Pharmacy Prior Authorization Master Opt-in/out Group list](#).

### How to submit prior authorization requests

- For a self-administered ustekinumab SC product (covered under the pharmacy benefit), submit the request using an electronic prior authorization, or ePA, tool such as CoverMyMeds® or Surescripts®.
- For an ustekinumab IV product that requires administration by a health care provider (covered under the medical benefit), submit the request through the NovoLogix® online tool.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

NovoLogix® is an independent company that provides an online prescription drug prior authorization tool for Blue Cross Blue Shield of Michigan and Blue Care Network.

Walgreens Specialty Pharmacy is an independent company that provides specialty pharmacy services covered under the pharmacy benefit for various Blue Cross Blue Shield of Michigan and Blue Care Network members with commercial plans.